A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00455442|
Recruitment Status : Completed
First Posted : April 3, 2007
Last Update Posted : September 19, 2008
|Condition or disease||Intervention/treatment||Phase|
|Weight-Gain Prevention||Drug: Mifepristone||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||57 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Two-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain in Healthy Male Volunteers|
|Study Start Date :||March 2007|
|Actual Study Completion Date :||July 2007|
- To determine the efficacy of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers.
- To determine the tolerability and safety of the administration of mifepristone and olanzapine in healthy male volunteers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00455442
|St. John's Medical College|
|Study Director:||Thad Block, MD||Corcept Therapeutics|